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Abstract
Background: Advances in generating genome-wide gene expression data have accelerated the development of 
molecular-based tumor classification systems. Tools that allow the translation of such molecular classification schemas 
from research into clinical applications are still missing in the emerging era of personalized medicine.
Results: We developed GliomaPredict as a computational tool that allows the fast and reliable classification of glioma 
patients into one of six previously published stratified subtypes based on sets of extensively validated classifiers 
derived from hundreds of glioma transcriptomic profiles. Our tool utilizes a principle component analysis (PCA)-based 
approach to generate a visual representation of the analyses, quantifies the confidence of the underlying subtype 
assessment and presents results as a printable PDF file. GliomaPredict tool is implemented as a plugin application for 
the widely-used GenePattern framework.
Conclusions: GliomaPredict provides a user-friendly, clinically applicable novel platform for instantly assigning gene 
expression-based subtype in patients with gliomas thereby aiding in clinical trial design and therapeutic decision-
making. Implemented as a user-friendly diagnostic tool, we expect that in time GliomaPredict, and tools like it, will 
become routinely used in translational/clinical research and in the clinical care of patients with gliomas.
Background
Gliomas are a family of malignant primary brain tumors
found in adults and children and are associated with a
high motility. Gliomas have historically been pathologi-
cally categorized based on their presumed histological
origin (i.e. astrocytic, oligodendroglial), as determined by
standard light microscopy-based cellular morphology [1].
These broad categories are further subdivided into the
"grade" of the tumor, a representation of the predicted rel-
ative aggressiveness of the tumor as determined by other
histology-based variables (i.e. necrosis, endothelial prolif-
eration, nuclear pleomorphism) [2]. While the histo-
pathological approach is still the standard utilized in the
clinic, it is well recognized that such classifications are
limited by significant intraobserver variability, the lack of
a biological basis for the designation, and the relatively
poor prognostic or therapeutic predictive utility of the
system [3,4]. A more objective, reproducible and biologi-
cally meaningful classification system is clearly needed.
The molecular stratification of glioma patients into
subtypes is the most direct way to translate genome-wide
high-throughput data into information that can be used
in a clinical setting. In the past, several groups have
attempted to identify brain tumor subtypes computation-
ally and stratify glioma patients into subtypes in terms of
the gene expression pattern of their classifiers. Limited
sample size (11-84 samples) and the subjective selection
of gene features, however, impaired the robustness and
clinical application of these classification methods [5-8].
Recently, we established a robust and reliable glioma clas-
sification system that includes six hierarchically-nested
subtypes and six sets of classifiers. Derived from tran-
scriptomic profiles of 159 glioma patients [9], samples are
separated into two main types: oligodendrogliomas
enriched (O) and glioblastomas enriched (G). While the
O group was further divided into OA and OB subtypes,
the G group was split into four subtypes, showing hierar-
chically-nested relationship designated as GA1, GA2,
GB1 and GB2. Several recent studies, using other large
and different databases, have likewise confirmed the exis-
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tence of four subgroups within the glioblastoma designa-
tion. Whether the four subgroups identified by these
different studies are all the same is not formally known at
this time, however, we have found significant overlap
between our four glioblastoma-enriched subtypes and
the four subtypes identified in two of the largest classifi-
cation studies of high-grade gliomas published to date
(data not shown) [10,11]. To translate our glioma classifi-
cation system into a clinically useful application that is
readily usable by clinicians and other statistically and
computationally naïve users, we implemented
GliomaPredict, a computational tool that allows anyone
to reliably predict the subtype of a new glioma patient
utilizing his/her tumor gene expression profile. As an
output, results are summarized in a printable PDF-file.
Implementation
Design objectives and specifications
We aimed to develop and implement a tool (GliomaPre-
dict) that could easily be used by physicians and clini-
cians, as well as laboratory researchers, allowing the fast
assignment of new patients to our previously-derived six
glioma subtypes with minimal technical difficulties and
user interventions. To ensure simplicity and eliminate
user intervention, all the data transfer steps in
GliomaPredict are handled by perl scripts. The naviga-
tion interfaces are simple and intuitive and the output is
presented both quantitatively and graphically to enhance
the visibility. Most importantly, we took the user-cen-
tered approach, designing the GliomaPredict as a plugin
application of GenePattern, a powerful genomic analysis
framewok that provides easy access to multiple applica-
tions for gene expression and SNP data analysis through a
web-based interface [12]. Data formats and the abun-
dance of other applications in GenePattern potentially
allow a further integrative analysis of patient data in the
future, combining data as disparate as genomic altera-
tions, ChIP-ChIP and protein-protein interactions.
Algorithm for assigning new patients to a subtype
GliomaPredict facilitates a supervised PCA using pre-
defined gene classifiers to assign new patients to the six
glioma subtypes [13]. The original algorithm was imple-
mented in MA TLAB (utilizing PRINCOMP function in
Statistics Toolbox) that can be mathematically described
as A = U￿Vt, where A is a data matrix, U is the basis
eigenvector and Vt is the transposed matrix of all eigen-
vectors. The PCA sequentially selects new orthogonal
coordinates (columns of U) capturing as much of the
remaining variation in the data as possible to effectively
reduce the dimensions of the data.
Algorithm for assessing prediction reliability
We computed the probability that an unknown sample
belongs to a certain glioma subtype using a supervised
PCA of gene classifiers; the PCA projects the unknown
sample to a n-dimensional space of reference dataset. The
proportion of variation of PCA components is used as a
weight vector to adjust distances. The weighted Euclidian
distance between two points U = (u1, u2,..., un) and V =
(v1,  v2,...,  vn) in a n-dimensional space is defined as
, where w  is the weight
vector we obtained from PCA analysis. Based on the
weighted Euclidian distance of unknown sample to the
centroid of the training samples in the reference set that
belong to a certain subtype we calculated the probability
that an unknown sample U belongs to a given subtype Ci
as ,  where  m
is the number of clusters, and   is the centroid of sam-
ples in subtype Ci.
Computing the relative distance of unknown samples to
other subtypes, we defined the relative distance as a mea-
sure of a sample being an outlier. In particular, the relative
distance rD of an unknown sample U to a subtype Ci is
computed as  ,
where σ is the standard deviation of distances between
the samples of a subtype Ci to the corresponding centroid
.
Installation
MATLAB version 7a or higher with Statistical T oolbox,
Perl version 5.8 or higher and GenePattern server version
3.0 or higher http://genepattern.org must be installed on
the server side. Acrobat viewer should be installed on the
client terminal for viewing the PDF-file, summarizing the
output. GliomaPredict was tested using Internet Explorer
(ver. 6.0 or higher) or Firefox (ver. 3.0 for Mac & PC or
higher) and Safari (ver. 3.2 or higher) (Additional file 1,
Additional file 2 and Additional file 3).
Results
Overview of GliomaPredict
We implemented GliomaPredict as a web-based applica-
tion that assigns a new patient to one of six predefined
glioma subtypes using three sets of classifiers. The pre-
diction is performed by running a supervised PCA analy-
sis using classifier-based gene expression in a reference
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set. The prediction probability and distances are com-
puted from the output of PCA analysis, and the new
patient is accordingly assigned to a subtype (Figure 1).
Using the projected mapping of the reference set classifi-
ers to discriminate between glioma subtypes, GliomaPre-
dict offers a flexible solution, allowing users to utilize
their laboratory and/or microarray platform specific sets
of gene classifiers.
Data requirements, workflow and output
GliomaPredict depends on a reference dataset to assign a
new patient to a particular tumor subtype. Therefore, the
reference dataset needs to be uploaded to the server dur-
ing installation. It takes three steps to create a reference
dataset: (i) profiling a set of glioma tumor arrays using
Affymetrix HG-U133A, HG-U133AB or HG-U133 plus 2
platforms, (ii) stratifying the arrays into the major sub-
types (six subtypes in our classification) using classifiers
[9], (iii) create a reference dataset file in MATLAB struc-
t u r e  f o r m a t  t h a t  c o n t a i n s  c l as s i f i e r  e x p r e s s i o n  o f  O / G ,
OA/OB and GA1/GA2/GB1/GB2 subtypes. The details
for creating a reference set are available in the
GliomaPredict manual. In addition, expression .cel files of
new glioma patients must be uploaded to a server before
the prediction analysis is run (Additional file 1, Addi-
tional file 2). The .cel files will be normalized automati-
cally after uploading and a .txt file containing normalized
expression values is created and stored into GliomaPre-
dict tool. A user can then select the new patient from the
patient pulldown list for prediction. While a user chooses
an array for classification, the classifier expression of that
patient is extracted and merged into the reference data-
set.
GliomaPredict then performs a supervised PCA analy-
sis using the PRINCOMP function as implemented in
Figure 1 Step-wise workflow of the GliomaPredict tool. Shaded 
area refers to functions and features included in the GliomaPredict 
tool. Specifically, our tool demands a transcriptomic .cel file of an un-
known patient sample as input; subsequently .cel file is automatically 
normalized. After filtering classifier-specific values, GliomaPredict per-
forms a supervised PCA analysis, provides a graphical representation of 
the PCA results and returns the quantitative measures that assess the 
reliability of the underlying patient-designated classification.
New patient
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Array
normalization
Classifier
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Microarray
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decision
Figure 2 User interfaces, prediction process and output exam-
ples of the GliomaPredict tool. Predicting the subtype of an un-
known patient sample, GliomaPredict provides a visual representation 
of the PCA of all reference samples in the subgroups. Indicating the lo-
cation of an unknown patient sample in these data clouds, GliomaPre-
dict calculates a probability that the underlying sample is of a certain 
subgroup. In addition, GliomaPredict also accounts for a distance of 
the underlying sample to the centroid of the subgroups.Li et al. BMC Medical Informatics and Decision Making 2010, 10:38
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MATLAB Statistics Toolbox, which sequentially selects
new orthogonal coordinates, capturing as much of the
remaining variation in the data as possible (Figure 2). The
PCA analysis effectively reduces the dimensionality of the
data and the first three uncorrelated coordinates from the
PCAview module were used to provide a visual represen-
tation of the subtypes, indicating the projection of the
unknown sample in predefined subtypes. In addition, the
output includes the prediction probability and distance of
the unknown sample to the centroid of the O and G
groups of reference samples. Depending on the initial
assessment, the patient's profile is further stratified either
into the OA/OB subtypes or into one out of four G sub-
types using a specific set of subtype specific gene classifi-
ers.
Usability evaluation
To ensure that the tool performs consistently and reliably,
we tested GliomaPredict on two levels. First, we set up a
core test dataset consisting of 9 samples of new patients.
The subtypes of these samples were assigned using
PAMR, and results were cross-validated extensively using
supervised hierarchical clustering and PCA to ensure the
re-assignments of these samples to subtypes are consis-
tent with the previous prediction. PAMR, which has a
shrunken centroid algorithm implemented in [14], was
originally used to derive the initial classifiers as reported
by Li et al. [9]. Our initial test results indicated that the
assignments of all the samples by the three methods were
consistent. We then used these samples as testers to vali-
date the performance consistency of GliomaPredict while
introducing each of the main features or functions. For
example, our original data were preprocessed using Win-
dows version of dChip [15]. To comply with the Mac
operating system and Linux platform, we chose to use a
gdChip package for array normalization, which is an
alternative version of dChip [16]. Our validation results
using the core test set indicated that the data normalized
using gdChip package perform consistently compared to
those normalized by the original Windows dChip in
terms of the subtype assignments. Secondly, we tested a
subset of 61 samples with assigned subtypes that were
predefined through an alternative approach using NMF
and k-means stratification in our previous study [9].
GliomaPredict yielded a over 96% prediction accuracy
when test samples were assigned to O/G main types, over
80% accuracy for predicting OA/OB subtypes and over
75% accuracy for predicting each of the four G subtypes
(Table 1).
Current utilization
GliomaPredict is currently running on the server of the
Neuro-Oncology Branch (NOB) at the National Institutes
of Health (NIH). Physicians and clinicians routinely use
the tool to predict the subtype of glioma patients. All
newly generated expression .cel files are automatically
uploaded to the server thereby making them readily avail-
able for analysis by the tool. Both clinicians and clinical/
translational glioma researchers use the software to pre-
dict the subtypes of a given patient for the purpose of
establishing the operative molecular pathways unique to
that specific glioma subtype and for the purpose of iden-
tifying cohorts of patients most likely to respond to
molecularly targeted agents based on our biological
annotation of each subgroup.
Discussion & Conclusions
We have previously reported on the creation of a glioma
classification system that includes six hierarchically
nested subtypes and six sets of classifiers to define each
subtype. To make this classification schema clinically use-
ful, we implemented GliomaPredict that utilizes gene
expression profiles to reliably and automatically assign a
glioma patient to one of the six predefined glioma sub-
types. The tool is based on a supervised PCA analysis
using classifiers that were derived previously and were
extensively tested and validated. We have demonstrated
that GliomaPredict performs reliably in assigning a new
patient to one of the six glioma subtypes with a mere click
of a button on any desktop computer connected to the
server. Since the reference set of samples and subtype-
specific gene classifiers can be taken from any given labo-
ratory, we are confident that GliomaPredict will perform
reliably across different laboratories and institutions.
More sophisticated computational methodologies and
strategies will continue to be developed to help interpret
and elucidate the underlying biology from the ever-grow-
ing body of "-omic" data being generated in gliomas and
other tumor types. Nevertheless, there is a pressing need
for user-friendly tools for computational naïve clinical
and translational scientists if we are to begin to translate
the advances in molecular and computational biology to
the clinic and to patients. The ability of a clinical scientist
to readily designate the molecular subtype of a particular
patient's tumor will allow the design of clinical trials that
m a y  e n r i c h  f o r  p a t i e n t s  m o r e  l i k e l y  t o  b e n e f i t  f r o m  a
novel molecularly targeted therapeutic agent based on
the signal transduction pathway activation status inher-
ent in that tumor subgroup. It is important to note, how-
ever, that the clinical utility of glioma molecular
subtyping has yet to be demonstrated. Nevertheless, it is
hypothesized that this type of tumor-specific molecular
data will ultimately lead to more accurate patient prog-
nostication and possibly even patient-specific therapy.
The ready ability to assign a given patient's tumor to a
particular subgroup by the simple click of a button on aLi et al. BMC Medical Informatics and Decision Making 2010, 10:38
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clinical computer, will aid clinical scientists in the testing
of that hypothesis. Thus, GliomaPredict represents a pro-
totype of the kinds of clinically useful computational
tools that may one day allow us to translate our rapidly
growing knowledge of molecular and genetic biology
toward the clinic and achieve the paradigm of personal-
ized medicine.
Availability and Requirements
Project name: GliomaPredict
Project home page: GliomaPredict is available from this
site: https://wiki.nci.nih.gov/display/NOBbioinf/Glioma
Predict
Operating system: Linux, Mac and Window OS
Requirements: MATLAB version 7.9.0 or higher, Perl
version 5.8.8 or higher
Licence: a free, open source tool.
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Table 1: Usability evaluation of glioma subtype predictions
Subtypes Prediction accuracy (%)
Train -> Test§ Test -> Test#
O versus G 96 96
OA versus OB 78 80
4 G subtypes 60 75
§Train -> Test: Use classifiers from train set, classifier expression 
from train set to predict subtypes of test set
#Test -> Test: Use classifiers from train set, classifier expression 
from test set to predict subtypes of test set